Lazari Capital Management Inc. Purchases New Position in Humacyte, Inc. $HUMA

Lazari Capital Management Inc. acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 13,044 shares of the company’s stock, valued at approximately $27,000.

A number of other hedge funds have also recently added to or reduced their stakes in HUMA. Ameriprise Financial Inc. bought a new stake in shares of Humacyte during the fourth quarter worth $58,000. BNP Paribas Financial Markets acquired a new position in Humacyte in the 4th quarter worth about $74,000. Bank of America Corp DE increased its holdings in Humacyte by 160.2% in the 4th quarter. Bank of America Corp DE now owns 597,319 shares of the company’s stock worth $3,016,000 after purchasing an additional 367,720 shares in the last quarter. Cetera Investment Advisers raised its position in Humacyte by 48.7% in the fourth quarter. Cetera Investment Advisers now owns 27,880 shares of the company’s stock valued at $141,000 after purchasing an additional 9,134 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Humacyte by 30.4% during the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company’s stock valued at $156,000 after purchasing an additional 7,188 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 591,685 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Brady W. Dougan sold 591,685 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale can be found here. Insiders sold a total of 4,482,090 shares of company stock valued at $7,466,382 over the last ninety days. 5.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Barclays assumed coverage on Humacyte in a report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price target on the stock. TD Cowen reduced their target price on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, August 12th. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Monday, September 15th. HC Wainwright dropped their price target on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, Wall Street Zen lowered Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, August 17th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Humacyte currently has an average rating of “Moderate Buy” and an average price target of $9.29.

Humacyte Stock Performance

Shares of HUMA stock opened at $1.73 on Monday. The firm has a 50 day moving average of $1.85 and a 200-day moving average of $2.01. The company has a market cap of $273.98 million, a price-to-earnings ratio of -3.84 and a beta of 1.88. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $6.77.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million. On average, equities analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.